Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

Does COMPASS Pathways PLC Sponsored ADR (CMPS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant IgA antibodies in the glomerular mesangium. Now, researchers have found that ...

Short-chain perfluorinated and polyfluorinated alkyl compounds (PFAS) such as perfluorobutanoic acid (PFBA) are increasingly ...

Panakeia ("the Company"), the world's first in silico multi-omics company, today unveiled landmark pathway activation data in cancers at the American Association for Cancer Research (AACR) Annual ...

First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...

Strategic reseller partnership expands market reach, combining expertise to help manufacturers improve planning, ...

CEO Tim Young provides candid update on Austin pilot findings, manufacturing strategy, and the company’s dual-track technology roadmapCORALVILLE, ...

Cemdisiran, an investigational small interfering RNA (siRNA) therapy targeting complement component 5 (C5), met both its ...

Brooks Koepka will be teeing it up with Shane Lowry at the Zurich Classic of New Orleans this week. The tournament is a vital ...